MA34827B1 - Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes - Google Patents

Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes

Info

Publication number
MA34827B1
MA34827B1 MA36110A MA36110A MA34827B1 MA 34827 B1 MA34827 B1 MA 34827B1 MA 36110 A MA36110 A MA 36110A MA 36110 A MA36110 A MA 36110A MA 34827 B1 MA34827 B1 MA 34827B1
Authority
MA
Morocco
Prior art keywords
robo1
hybrid protein
treating hepatocarcinoma
hepatocarcinoma
treating
Prior art date
Application number
MA36110A
Other languages
English (en)
Inventor
Frederique Dol-Gleizes
Genevieve Gueguen-Dorbes
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45440542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34827(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR1061163A external-priority patent/FR2969617A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34827B1 publication Critical patent/MA34827B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation d'une protéine recombinante Robo1-Fc pour le traitement du cancer, en particulier d'un hépatocarcinome.
MA36110A 2010-12-23 2011-12-22 Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes MA34827B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1061163A FR2969617A1 (fr) 2010-12-23 2010-12-23 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs.
EP11306336 2011-10-14
PCT/EP2011/073739 WO2012085178A1 (fr) 2010-12-23 2011-12-22 Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes

Publications (1)

Publication Number Publication Date
MA34827B1 true MA34827B1 (fr) 2014-01-02

Family

ID=45440542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36110A MA34827B1 (fr) 2010-12-23 2011-12-22 Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes

Country Status (18)

Country Link
US (1) US20130273049A1 (fr)
EP (1) EP2655408B1 (fr)
JP (1) JP2014507395A (fr)
KR (1) KR20130132880A (fr)
CN (1) CN103703021A (fr)
AR (1) AR084541A1 (fr)
AU (1) AU2011347250B2 (fr)
CA (1) CA2820781A1 (fr)
CL (1) CL2013001861A1 (fr)
CO (1) CO6741197A2 (fr)
EA (1) EA201390955A1 (fr)
MA (1) MA34827B1 (fr)
MX (1) MX2013007421A (fr)
PH (1) PH12013501205A1 (fr)
SG (1) SG191060A1 (fr)
UY (1) UY33833A (fr)
WO (1) WO2012085178A1 (fr)
ZA (1) ZA201305266B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
HRP20190116T1 (hr) 2012-01-05 2019-03-08 Boston Medical Center Corporation Slit-robo signaliziranje, namijenjeno dijagnosticiranju i liječenju bubrežne bolesti
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104873986A (zh) * 2015-03-23 2015-09-02 广东药学院 一种治疗肝脏纤维化的siRNA及其应用
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
KR20200016292A (ko) 2017-06-02 2020-02-14 화이자 인코포레이티드 재조합 robo2 단백질, 조성물, 방법 및 그의 용도
WO2020175931A1 (fr) * 2019-02-27 2020-09-03 주식회사 대웅제약 Composition comprenant du lrrd2 slit3 couplé à l'albumine pour la prévention ou le traitement d'une maladie des muscles
TW202511284A (zh) * 2023-09-14 2025-03-16 大陸商北京拓界生物醫藥科技有限公司 包含robo結構域的蛋白及其醫藥用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
WO1999020764A1 (fr) * 1997-10-20 1999-04-29 The Regents Of The University Of California Robo : une famille de polypeptides et d'acides nucleiques impliques dans le guidage des nerfs
US7939497B2 (en) * 2002-03-08 2011-05-10 Shanghai Institutes For Biological Sciences, Cas Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
CA2565175C (fr) * 2004-03-31 2017-12-19 Chugai Seiyaku Kabushiki Kaisha Diagnostic du cancer et traitement utilisant l'anticorps anti-robo1
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
EP3067368A1 (fr) * 2007-04-27 2016-09-14 Genentech, Inc. Anticorps anti-cd4 puissants, stables et non immunosuppresseurs
CA2699411A1 (fr) * 2007-09-14 2009-03-19 Scil Technology Gmbh Facteurs neuroendocrinaux pour le traitement de maladies neurodegeneratives
FR2958936A1 (fr) * 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用

Also Published As

Publication number Publication date
PH12013501205A1 (en) 2013-07-29
CA2820781A1 (fr) 2012-06-28
SG191060A1 (en) 2013-07-31
EP2655408B1 (fr) 2016-07-06
US20130273049A1 (en) 2013-10-17
ZA201305266B (en) 2014-09-25
UY33833A (es) 2012-07-31
WO2012085178A1 (fr) 2012-06-28
CN103703021A (zh) 2014-04-02
EA201390955A1 (ru) 2013-11-29
EP2655408A1 (fr) 2013-10-30
CO6741197A2 (es) 2013-08-30
JP2014507395A (ja) 2014-03-27
MX2013007421A (es) 2014-02-03
KR20130132880A (ko) 2013-12-05
AU2011347250A1 (en) 2013-05-02
CL2013001861A1 (es) 2014-04-04
AU2011347250B2 (en) 2015-06-04
AR084541A1 (es) 2013-05-22

Similar Documents

Publication Publication Date Title
MA35210B1 (fr) Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
MA37740A1 (fr) Seringue
EA201171367A1 (ru) Винилиндазолильные соединения
EP2828100A4 (fr) Traitement de surface pour une surface d'implant
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EP2885751A4 (fr) Traitement d'image pour une validation de crédit
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
EP2683382A4 (fr) Régimes posologiques pour le traitement de la maladie de fabry
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EP2568999A4 (fr) Acth pour le traitement de la sclérose latérale amyotrophique
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
FR2975600B1 (fr) Agents pour le traitement de tumeurs
EP2837381A4 (fr) Utilisation d'agents modificateurs de l'environnement péritumoral pour le traitement du cancer
MA34878B1 (fr) Utilisation de ligands sigma pour la douleur des cancers des os
EP2788378A4 (fr) Thérapie d'association pour le traitement du cancer
EP2579863A4 (fr) Composés pour le traitement de la mastite bovine
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
EP2575829A4 (fr) Kit pour le traitement de l'onychomycose par l'oxyde nitrique
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
EP2758134A4 (fr) Buprénorphine pour le traitement d'une tendance suicidaire aiguë
MA34098B1 (fr) Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée